{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05226793",
            "orgStudyIdInfo": {
                "id": "054.PHA.2021.R"
            },
            "organization": {
                "fullName": "Methodist Health System",
                "class": "OTHER"
            },
            "briefTitle": "Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients",
            "officialTitle": "Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients",
            "therapeuticArea": [
                "Other"
            ],
            "study": "medication-use-evaluation-for-enoxaparin-in-hospitalized-covid-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-11-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-17",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11-17",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-02-03",
            "studyFirstSubmitQcDate": "2022-02-03",
            "studyFirstPostDateStruct": {
                "date": "2022-02-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Methodist Health System",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.",
            "detailedDescription": "Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.\n\nEPIC will be queried for data for this medication use evaluation, including the patient's age, sex, weight/BMI, ICU status, maximum D-dimer level, enoxaparin dose received, development of DVT or PE, incidence and type of bleeding events, readmission status, and mortality. Other patient specific factors such as the CCI score, Padua score, and IMPROVE score will be calculated using online risk assessment tools.\n\nTo calculate the CCI score, a search function will be used to analyze the patient's health information in order to determine their age, history of myocardial infarction, congestive heart failure, peripheral vascular disease, stroke or transient ischemic attack, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes mellitus, kidney function, cancer status, blood dyscrasias, and HIV status to estimate their 10-year probability of survival.\n\nTo calculate the Padua score, each patient must be evaluated for cancer status, history of VTE, mobility status, history of thrombophilic conditions, recent trauma or surgery, age, heart and/or respiratory failure, acute myocardial infarction and/or respiratory failure status, acute infection and/or rheumatologic disorder, obesity, and ongoing hormonal treatment. If a patient scores a 4 or more, then pharmacologic prophylaxis would be indicated.\n\nLastly, to calculate each patient's bleeding risk, the IMPROVE bleeding risk assessment will be used. For this tool, the patient's age, gender, renal function, liver function, platelet count, ICU status, the presence of a central venous catheter, active gastrointestinal ulcer, history of bleeding in the previous three months, presence of rheumatic disease, and active malignancy are needed to calculate the risk. If the patient scores a 7 or higher on the assessment, they are at an increased risk for bleeding."
        },
        "conditionsModule": {
            "conditions": [
                "Venous Thromboembolism"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_ONLY",
                "timePerspective": "RETROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 400,
                "type": "ESTIMATED"
            }
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Enoxaparin dose (appropriate for kidney function)",
                    "description": "Enoxaparin dose",
                    "timeFrame": "2021-2022"
                },
                {
                    "measure": "Charlson comorbidity index (CCI) score",
                    "description": "(CCI) score",
                    "timeFrame": "2021-2022"
                },
                {
                    "measure": "Padua prediction score for risk of VTE",
                    "description": "Padua prediction score",
                    "timeFrame": "2021-2022"
                },
                {
                    "measure": "IMPROVE [International Medical Prevention Registry on VTE] bleeding risk assessment score",
                    "description": "IMPROVE \\[International Medical Prevention Registry on VTE\\] bleeding risk assessment score",
                    "timeFrame": "2021-2022"
                },
                {
                    "measure": "ICU status",
                    "description": "ICU status",
                    "timeFrame": "2021-2022"
                },
                {
                    "measure": "Number of thromboembolic events",
                    "description": "Number of thromboembolic events",
                    "timeFrame": "2021-2022"
                },
                {
                    "measure": "Length of stay",
                    "description": "Days",
                    "timeFrame": "2021-2022"
                },
                {
                    "measure": "Readmissions for DVT and/or PE",
                    "description": "Readmissions for DVT and/or PE",
                    "timeFrame": "2021-2022"
                },
                {
                    "measure": "In-hospital mortality with associated DVT or PE",
                    "description": "In-hospital mortality with associated DVT or PE",
                    "timeFrame": "2021-2022"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Bleeding events",
                    "description": "Bleeding events",
                    "timeFrame": "2021-2022"
                },
                {
                    "measure": "Type of bleeding event",
                    "description": "Type of bleeding event",
                    "timeFrame": "2021-2022"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nEffectiveness of intermediate-intensity vs standard prophylactic enoxaparin regimens on preventing DVT and/or PE in patients with COVID-19, measured using the following variables:\n\n* Enoxaparin dose (appropriate for kidney function)\n* Charlson comorbidity index (CCI) score\n* Padua prediction score for risk of VTE\n* IMPROVE \\[International Medical Prevention Registry on VTE\\] bleeding risk assessment score\n* ICU status\n* Number of thromboembolic events\n* Length of stay\n* Readmissions for DVT and/or PE\n* In-hospital mortality with associated DVT or PE\n\nExclusion Criteria:\n\n* Safety of intermediate-intensity vs standard prophylactic enoxaparin regimens in patients with COVID-19, measured using the following variables:\n\n  * Bleeding events\n  * Type of bleeding event",
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients age 18 years or older hospitalized with COVID-19 on prophylactic/non-therapeutic enoxaparin from January 1, 2021 to January 31, 2021\n\nPatients that do not have any other indication for use of enoxaparin (i.e., active DVT/PE, atrial fibrillation, etc.)",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Crystee Cooper, DHEd",
                    "role": "CONTACT",
                    "phone": "214-947-1280",
                    "email": "clinicalresearch@mhd.com"
                },
                {
                    "name": "Zaid Haddadin, MS",
                    "role": "CONTACT",
                    "phone": "214-947-1280",
                    "email": "clinicalresearch@mhd.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Betina Daniel, PharmD",
                    "affiliation": "Methodist",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Methodist Richardson Medical Center",
                    "status": "RECRUITING",
                    "city": "Richardson",
                    "state": "Texas",
                    "zip": "75082",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Crystee Cooper, DHEd",
                            "role": "CONTACT",
                            "phone": "214-947-1280",
                            "email": "clinicalresearch@mhd.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.94818,
                        "lon": -96.72972
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013923",
                    "term": "Thromboembolism"
                },
                {
                    "id": "D000054556",
                    "term": "Venous Thromboembolism"
                }
            ],
            "ancestors": [
                {
                    "id": "D000016769",
                    "term": "Embolism and Thrombosis"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2561",
                    "name": "COVID-19",
                    "relevance": "LOW"
                },
                {
                    "id": "M16682",
                    "name": "Thromboembolism",
                    "asFound": "Thromboembolism",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27780",
                    "name": "Venous Thromboembolism",
                    "asFound": "Venous Thromboembolism",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7784",
                    "name": "Embolism",
                    "relevance": "LOW"
                },
                {
                    "id": "M16686",
                    "name": "Thrombosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M19128",
                    "name": "Embolism and Thrombosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M20152",
                    "name": "Enoxaparin",
                    "relevance": "LOW"
                },
                {
                    "id": "M137075",
                    "name": "Enoxaparin sodium",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "FiAg",
                    "name": "Fibrinolytic Agents"
                },
                {
                    "abbrev": "AnCoag",
                    "name": "Anticoagulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}